Pharmacomers™ small, unique chemical groups that can replace traditional heterocyclic synthons (< 150 MW) to predictably improve the PK and PD profile of drugs. Pharmacomers™ work by allowing the conformation of a drug to adjust in response to the changing physiological environments encountered from pill to target;
Surface chemical techniques based on self-assembled monolayers (SAMs) on gold that are used to characterize the biophysical properties of Pharmacomers™ and to predict their impact on the PK profiles of drugs;
Computational tools that are used to help initially design Pharmacomers™ and to predict their interactions with target proteins
